08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
As we reported, New York State has enacted laws prohibiting mandatory arbitration of sexual harassme...
Read More >
It’s the end of the year and while everyone is busy, employers in California should be aware of new...
Read More >
Q: If I am designating an employee as a key employee under the FMLA, can I just fire them on the fir...
Read More >
The proliferation of the gig economy has created a renewed interest in the distinction between emplo...
Read More >
Before employers implement their proposed workforce changes resulting from the finalization of the n...
Read More >
The past decade’s robust mergers and acquisitions volume sparked the rapid growth of representation...
Read More >